Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986738 | 0.93 | HSP90AB1 (0.45) | KDM4EMEN1KMT2AALDH1A1POLB | |
| SCHEMBL4990762 | 0.88 | MTNR1B (0.47) | — | |
| SCHEMBL4982815 | 0.87 | MEN1 (0.45) | KDM4EMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL4985321 | 0.85 | CFTR (0.44) | SMN1; SMN2OPRM1POLB | |
| SCHEMBL4990688 | 0.84 | KDM4E (0.46) | KDM4EMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL4985028 | 0.84 | KDM4E (0.45) | KDM4EMEN1KMT2AOPRM1ALDH1A1 | |
| SCHEMBL4988442 | 0.84 | ABCB1 (0.39) | POLB | |
| SCHEMBL4983018 | 0.83 | KMT2A (0.45) | KDM4EMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL4985271 | 0.83 | MEN1 (0.37) | KDM4EMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL4982516 | 0.83 | DHFR (0.45) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | KDM4E 4128/4885SMN1; SMN2 4369/4885MEN1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.